Novel Selective Beta-Agonist Improves Lung Function in COPD: Preliminary Analysis

Web Exclusives
Wayne Kuznar

Anew, highly selective intravenous (IV) beta-agonist in development—MN-221 (bedoradrine sulfate)—improves lung function in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD), according to a dose-ranging study presented at the meeting.

In development for the treatment of acute exacerbations of asthma and COPD, MN-221 has higher selectivity for the beta2-receptors than the currently used beta-agonists (ie, albuterol, levalbuterol, terbutaline), which suggests that the cardiac-stimulating action on beta1-receptors may be reduced with this investigational agent. Therefore, MN-221 may reduce bronchospasm, while minimizing cardiovascular complications.

James Pearle, MD, and colleagues at California Research Medical Group in Fullerton, examined 3 dose levels of MN-221 (300 μg, 600 μg, and 1200 μg IV) in 16 patients with stable, moderate- to-severe COPD. The patients were randomized to receive either MN-221 or placebo in a 3:1 ratio—half of the dose was given over 15 minutes, followed by the remaining dose over 45 minutes, for a total 1-hour infusion.

Lung function improved with all 3 doses; the improvement was significant compared with placebo at the 600-μg and 1200-μg doses. The forced expiratory volume in 1 second (FEV1) increases from baseline were 9.2% with the 300-μg dose (not a significant difference), 16.2% with the 600-μg dose (P = .02), and 21.5% with the 1200-μg dose (P = .025). In comparison, FEV1 declined by 4% in patients receiving placebo infusion.

The researchers noted that MN-221 at doses of 600 μg and 1200 μg improved lung function for at least 6 hours compared with placebo

Related Items
The Pediatric MATCH Study: Actionable Targets Found in 25% of Young Patients with Cancer
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Pediatric Cancer
Autologous Mesothelin-Targeted T-Cells Induce Responses in Pleural Solid Tumors
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Selective, Small-Molecule DRD2 Antagonist Induces Tumor Regression in Recurrent High-Grade Glioma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Emerging Therapies
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Cholangiocarcinoma
Larotrectinib Has Wide-Ranging Efficacy in Advanced Solid Tumors with NTRK Gene Fusion
Wayne Kuznar
August 2019, Vol 12, Special Issue: Payers’ Perspectives In Oncology: ASCO 2019 Highlights published on August 16, 2019 in Biomarkers
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME